{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:39:51Z","timestamp":1791567591231,"version":"4.3.4"},"reference-count":41,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Hypertriglyceridemia is a common lipid disorder linked to residual cardiovascular risk and acute pancreatitis despite standard therapy. Olezarsen, an antisense oligonucleotide targeting apolipoprotein C\u2010III (ApoC\u2010III), offers a novel triglyceride\u2010lowering strategy. We performed an updated meta\u2010analysis to evaluate its efficacy and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and Materials<\/jats:title>\n                    <jats:p>We performed a meta\u2010analysis of randomised controlled trials (RCTs) identified through PubMed, Cochrane, Scopus and Web of Science up to December 2025. Random\u2010effects models were used to pool mean percentage changes (MDs) and risk ratios (RRs) with 95% confidence intervals (CIs). PROSPERO ID: CRD420261279110.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Six RCTs with 2676 participants were analysed. Olezarsen significantly reduced triglycerides at 50\u2009mg (MD \u221246.61%, 95% CI \u221249.59 to \u221243.64) and 80\u2009mg (MD \u221254.37%, 95% CI \u221261.26 to \u221247.48), both\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001. ApoC\u2010III was markedly reduced (50\u2009mg: MD \u221263.51%, 95% CI \u221274.18 to \u221252.84; 80\u2009mg: MD \u221266.88%, 95% CI \u221277.91 to \u221255.85; both\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). Non\u2010HDL\u2010C also decreased significantly (50\u2009mg: MD \u221221.41%, 95% CI \u221225.12 to \u221217.70;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001; 80\u2009mg: MD \u221225.28%, 95% CI \u221233.99 to \u221216.58;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009= 0.001). LDL\u2010C increased modestly at 50\u2009mg (MD 17.58%, 95% CI 0.24 to 34.93;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.047). Olezarsen reduced acute pancreatitis risk (50\u2009mg: RR 0.16, 95% CI 0.05\u20130.48;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001; 80\u2009mg: RR 0.33, 95% CI 0.14\u20130.76;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.009). Overall adverse events were comparable to placebo, while ALT\/AST \u2265\u20093\u2009\u00d7\u2009ULN increased with 80\u2009mg (RR 2.56, 95% CI 1.20\u20135.44;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Olezarsen provides substantial triglyceride reduction with favourable effects on atherogenic lipoproteins and a tolerable short\u2010term safety profile. Longer\u2010term trials are needed to confirm cardiovascular outcomes and safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.70716","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T08:44:16Z","timestamp":1775551456000},"page":"5133-5148","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and Safety of Olezarsen in Hypertriglyceridemia: An Updated Meta\u2010Analysis of Randomised Controlled Trials"],"prefix":"10.1111","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2718-8627","authenticated-orcid":false,"given":"Ahmed","family":"Emara","sequence":"first","affiliation":[{"name":"Faculty of Medicine Al\u2010Azhar University  Cairo Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Mansour","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Al\u2010Azhar University  Cairo Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heba","family":"Aboeldahab","sequence":"additional","affiliation":[{"name":"Clinical Research Department El\u2010Gomhoria General Hospital, MOHP  Alexandria Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameer","family":"Awashra","sequence":"additional","affiliation":[{"name":"Department of Medicine An\u2010Najah National University  Nablus West Bank Palestine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar F.","family":"Abbas","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Al\u2010Azhar University  Cairo Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza A.","family":"Abdul\u2010Hafez","sequence":"additional","affiliation":[{"name":"Department of Medicine An\u2010Najah National University  Nablus West Bank Palestine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal A.","family":"Alsubaiei","sequence":"additional","affiliation":[{"name":"Kuwait Institute for Medical Specializations  Kuwait City Kuwait"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najat","family":"AlSejari","sequence":"additional","affiliation":[{"name":"Kuwait Institute for Medical Specializations  Kuwait City Kuwait"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamad","family":"Salman Saif","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine King Hamad University Hospital  Busaiteen Bahrain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdalhakim","family":"Shubietah","sequence":"additional","affiliation":[{"name":"Department of Medicine Advocate Illinois Masonic Medical Center  Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Mhanna","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine University of Iowa  Iowa city Iowa USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"e_1_2_15_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40119-020-00170-x"},{"key":"e_1_2_15_3_1","volume-title":"StatPearls","author":"Karanchi H.","year":"2025"},{"key":"e_1_2_15_4_1","doi-asserted-by":"publisher","DOI":"10.2174\/1573403X14666180123165542"},{"key":"e_1_2_15_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000014378"},{"key":"e_1_2_15_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2017.31"},{"key":"e_1_2_15_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-017-0625-0"},{"key":"e_1_2_15_8_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.R082271"},{"key":"e_1_2_15_9_1","doi-asserted-by":"publisher","DOI":"10.12997\/jla.2021.10.1.88"},{"key":"e_1_2_15_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/2050640618755002"},{"key":"e_1_2_15_11_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00474"},{"key":"e_1_2_15_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-023-01080-8"},{"key":"e_1_2_15_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1308027"},{"key":"e_1_2_15_14_1","doi-asserted-by":"publisher","DOI":"10.61797\/ijetit.v5i1.334"},{"issue":"6","key":"e_1_2_15_15_1","first-page":"493","article-title":"Apolipoprotein C\u2010III, Familial Chylomicronemia Syndrome, and Olezarsen","volume":"5","author":"Valdivielso P.","year":"2024","journal-title":"Medicus"},{"key":"e_1_2_15_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1307095"},{"key":"e_1_2_15_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2507227"},{"key":"e_1_2_15_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00210\u2010025\u201004406\u20102"},{"key":"e_1_2_15_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2512761"},{"key":"e_1_2_15_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_2_15_21_1","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Cochrane","year":"2024"},{"key":"e_1_2_15_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_2_15_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD"},{"key":"e_1_2_15_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/ebmental-2019-300117"},{"key":"e_1_2_15_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/biom.12817"},{"key":"e_1_2_15_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.10.007"},{"key":"e_1_2_15_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-017-0315-7"},{"key":"e_1_2_15_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1187"},{"key":"e_1_2_15_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2402309"},{"key":"e_1_2_15_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2400201"},{"key":"e_1_2_15_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab820"},{"key":"e_1_2_15_32_1","volume-title":"FDA Approves Drug to Reduce Triglycerides in Adult Patients With Familial Chylomicronemia Syndrome","author":"FDA","year":"2025"},{"key":"e_1_2_15_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-017-0697-3"},{"key":"e_1_2_15_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2022.02.008"},{"key":"e_1_2_15_35_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252312759"},{"key":"e_1_2_15_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404143"},{"key":"e_1_2_15_37_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2024.0959"},{"key":"e_1_2_15_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2025.03.003"},{"key":"e_1_2_15_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(24)00040-8"},{"key":"e_1_2_15_40_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11040982"},{"key":"e_1_2_15_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200325"},{"key":"e_1_2_15_42_1","volume-title":"Efficacy and Safety of Olezarsen in Treating Hypertriglyceridemia: A Systematic Review and Meta\u2010Analysis of Randomized Controlled Trials","author":"Discover Medicine","year":"2025"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.70716","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/full-xml\/10.1111\/dom.70716","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.70716","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T03:02:49Z","timestamp":1780455769000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.70716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1111\/dom.70716"],"URL":"https:\/\/doi.org\/10.1111\/dom.70716","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.70716\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70716\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70716\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70716\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70716\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70716\/v2\/review1","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]},"assertion":[{"value":"2026-01-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}